Advertisement

Topics

Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration

10:40 EDT 16 May 2019 | Genetic Engineering News

Genentech, a Member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac disease (CD) based on Parvus’ Navacim™ precision medicine platform. Navacims are designed to help protect against autoimmune disease by triggering a […]

The post Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration

NEXT ARTICLE

More From BioPortfolio on "Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...